DSGN Stock Analysis: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$13.74
0.04 (0.29%)
▲
5d:
+23.34%
30d:
+24.8%
90d:
+35.1%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: DSGN is 11.6% above its trading range ($12.31). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: DSGN is 11.6% above its trading range ($12.31). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $13.74, which is considered extended relative to its 30-day fair value range of $10.12 to $12.31.
Technical Outlook: Technically, DSGN is in a uptrend. The price is approaching resistance at $14.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DSGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.00 (+53.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DSGN is in a uptrend. The price is approaching resistance at $14.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DSGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.00 (+53.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.12 -
$12.31
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BEARISH: Price significantly overextended (+11.6% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 53.3% below Wall St target ($21.00)
- WARNING: Recommendation downgraded due to 11.6% overvaluation
Trading Range Analysis
30-Day Trading Range
$10.12 -
$12.31
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.90
(13.8%)
Support & Resistance Levels
Support Level
$10.25
Resistance Level
$14.11
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.38
Wall Street Target
$21.00
(+53.3%)
Share & Embed Analysis
Last updated: June 23, 2026 4:52 PM ET
Data refreshes hourly during market hours. Next update: 5:52 PM
Data refreshes hourly during market hours. Next update: 5:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
